[go: up one dir, main page]

ECSP13013009A - INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA - Google Patents

INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA

Info

Publication number
ECSP13013009A
ECSP13013009A ECSP13013009A ECSP13013009A EC SP13013009 A ECSP13013009 A EC SP13013009A EC SP13013009 A ECSP13013009 A EC SP13013009A EC SP13013009 A ECSP13013009 A EC SP13013009A
Authority
EC
Ecuador
Prior art keywords
tropomiosine
pirimidine
pirrolo
inhibitors related
quinase
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Anthony Stupple
Thomas Ryckmans
Mark David Andrews
Kart Richard Gibson
Sarah Elizabeth Skerratt
Sharanjeet Kaur Bagal
Kiyoyuki Omoto
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013009(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of ECSP13013009A publication Critical patent/ECSP13013009A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I) y sus sales aceptables para uso farmacéutico donde los sustituyentes son como se describen en la presente, y su uso en medicina, en particular como antagonistas de Trk.
ECSP13013009 2011-04-05 2013-11-05 INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA ECSP13013009A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471758P 2011-04-05 2011-04-05

Publications (1)

Publication Number Publication Date
ECSP13013009A true ECSP13013009A (es) 2013-12-31

Family

ID=45937493

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013009 ECSP13013009A (es) 2011-04-05 2013-11-05 INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA

Country Status (32)

Country Link
US (2) US8846698B2 (es)
EP (1) EP2694509B1 (es)
JP (1) JP5595616B2 (es)
KR (1) KR20130133905A (es)
CN (1) CN103534257A (es)
AP (1) AP2013007159A0 (es)
AR (1) AR085852A1 (es)
AU (1) AU2012238369A1 (es)
BR (1) BR112013025792A2 (es)
CA (1) CA2832291C (es)
CL (1) CL2013002821A1 (es)
CO (1) CO6801740A2 (es)
CR (1) CR20130470A (es)
CU (1) CU20130129A7 (es)
DO (1) DOP2013000221A (es)
EA (1) EA201391239A1 (es)
EC (1) ECSP13013009A (es)
ES (1) ES2581848T3 (es)
GE (1) GEP20156417B (es)
GT (1) GT201300236A (es)
IL (1) IL228590A0 (es)
MA (1) MA35024B1 (es)
MX (1) MX2013011612A (es)
NI (1) NI201300103A (es)
PE (1) PE20141050A1 (es)
PH (1) PH12013502020A1 (es)
SG (1) SG193513A1 (es)
TN (1) TN2013000394A1 (es)
TW (1) TWI443101B (es)
UA (1) UA108926C2 (es)
UY (1) UY34004A (es)
WO (1) WO2012137089A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187472B2 (en) * 2012-05-11 2015-11-17 Abbvie Inc. NAMPT inhibitors
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
JP2015531393A (ja) * 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
EP2903989A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
JP6506248B2 (ja) 2013-03-14 2019-04-24 ゾーン・ロイヤリティズ・アンド・マイルストーンズ・エルエルシー 二環式鎮痛化合物
JP2016169161A (ja) * 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
TWI663159B (zh) 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
KR102380609B1 (ko) 2013-12-12 2022-03-30 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 알킬 화합물 및 합성
EP3083602A1 (en) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
JP2017508729A (ja) * 2014-01-24 2017-03-30 アッヴィ・インコーポレイテッド フロ−３−カルボキサミド誘導体および使用方法
ES2874533T3 (es) * 2014-02-05 2021-11-05 VM Oncology LLC Composiciones de compuestos y usos de los mismos
US10654812B2 (en) 2014-03-07 2020-05-19 Recurium Ip Holdings Llc Propellane derivates and synthesis
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
EP3140298A1 (en) * 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
CN103992319B (zh) * 2014-05-27 2015-09-16 天津市斯芬克司药物研发有限公司 一种吡啶羧酸类化合物的制备方法
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
KR20170048588A (ko) * 2014-09-17 2017-05-08 카리라 파마슈티컬스, 아이앤씨. 바이사이클릭 화합물
MY195799A (en) 2014-12-18 2023-02-21 Genzyme Corp Pharmaceutical Formulations of Tropomyosin-Related Kinase (TRK) Inhibitors
US10202376B2 (en) 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN105837574B (zh) * 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3475280B1 (en) * 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
CN107011347B (zh) * 2017-04-18 2019-01-18 华东师范大学 一种4-氯-7H-吡咯并[2,3-d]嘧啶的合成方法
MX389668B (es) 2017-05-15 2025-03-20 Recurium Ip Holdings Llc Compuestos biciclo[1.1.1]pentilo sustituidos y uso de los mismos para el tratamiento del dolor y fiebre.
ES2968421T3 (es) 2017-06-23 2024-05-09 San Diego State Univ Research Foundation Atropisomerismo para la selectividad potenciada de inhibidor de cinasa
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3774800B1 (en) * 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
CN109053575A (zh) * 2018-08-24 2018-12-21 遵义医学院 3-环丙基-1-甲基-1h-吡唑-4-甲醛的制备工艺
WO2020084389A1 (en) * 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
EP4357347B1 (en) * 2021-06-21 2024-12-11 Henan Medinno Pharmaceutical Technology Co., Ltd. Trk kinase inhibitor compound and use thereof
AU2024249981A1 (en) 2023-04-06 2025-10-16 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
WO2025007055A1 (en) * 2023-06-29 2025-01-02 Volastra Therapeutics, Inc. Aryl indol-3-yl ketone and aryl indazol-3-yl ketone inhibitors of kif18a

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW438796B (en) 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CA2283961A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
GB0218168D0 (en) * 2002-08-06 2002-09-11 Astrazeneca Ab Compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
JP2007517868A (ja) 2004-01-07 2007-07-05 アストラゼネカ アクチボラグ 治療薬ｉ
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
CA2566160C (en) * 2004-05-27 2011-01-18 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
MX2007014377A (es) * 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
WO2007042545A1 (en) 2005-10-14 2007-04-19 Neurosearch A/S Imidazole derivatives and their use for modulating the gaba-a receptor complex
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
RU2323058C1 (ru) 2006-07-12 2008-04-27 ООО Научно-внедренческий центр "Машины и оборудование для энергетики" Способ формирования наружной резьбы на концевом участке трубной заготовки
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
CA2673736A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CA2681572C (en) 2007-03-23 2014-02-11 Icagen, Inc. Inhibitors of ion channels
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
HRP20150355T1 (hr) 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症

Also Published As

Publication number Publication date
IL228590A0 (en) 2013-12-31
CN103534257A (zh) 2014-01-22
PE20141050A1 (es) 2014-08-30
GEP20156417B (en) 2015-12-25
EA201391239A1 (ru) 2014-03-31
AU2012238369A1 (en) 2013-10-03
PH12013502020A1 (en) 2018-04-11
TW201302757A (zh) 2013-01-16
WO2012137089A1 (en) 2012-10-11
TWI443101B (zh) 2014-07-01
KR20130133905A (ko) 2013-12-09
UA108926C2 (ru) 2015-06-25
MA35024B1 (fr) 2014-04-03
NZ615557A (en) 2014-08-29
EP2694509A1 (en) 2014-02-12
NI201300103A (es) 2014-02-12
ES2581848T3 (es) 2016-09-07
MX2013011612A (es) 2013-10-17
JP5595616B2 (ja) 2014-09-24
SG193513A1 (en) 2013-10-30
CA2832291C (en) 2015-12-01
US8846698B2 (en) 2014-09-30
EP2694509B1 (en) 2016-05-18
US20120258950A1 (en) 2012-10-11
UY34004A (es) 2012-11-30
US20140364415A1 (en) 2014-12-11
CR20130470A (es) 2013-10-16
DOP2013000221A (es) 2014-03-16
JP2014510131A (ja) 2014-04-24
AP2013007159A0 (en) 2013-10-31
CO6801740A2 (es) 2013-11-29
CL2013002821A1 (es) 2014-02-21
CU20130129A7 (es) 2014-01-29
GT201300236A (es) 2015-08-04
AR085852A1 (es) 2013-10-30
CA2832291A1 (en) 2012-10-11
BR112013025792A2 (pt) 2018-04-24
TN2013000394A1 (fr) 2015-01-20

Similar Documents

Publication Publication Date Title
ECSP13013009A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
DOP2014000203A (es) Compuestos de heterociclilo
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY33078A (es) Derivados de imidazoquinolina
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
SV2010003472A (es) Compuestos de pirazol
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
MX2015008233A (es) Nuevos derivados de quinolona.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
UY33240A (es) ?análogos de péptidos?.
CU20100158A7 (es) Pirrolo[2,3-d]pirimidinas y usos de las mismas como inhibidores de cinasa de tirosina
CU20100018A7 (es) Compuestos de pirazol
CU20100125A7 (es) Derivados bis-(sulfonilamino) para uso en terapia
CU20100094A7 (es) Derivados bis-(sulfonilamino) en terapia 066
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa